Krystal Biotech, Inc.
KRYSNasdaq
$354.86
↑ +3.8%Jul 17 close · end-of-day
Price
1Y↑ +136.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$10.8B
Enterprise Value
$10.0B
P/E
47.5
P/S
25.9
P/B
8.5
EV/EBITDA
54.2
PEG
—
FCF Yield
2.2%
Dividend Yield
—
Revenue (TTM)
$417.3M
Net Income (TTM)
$225.0M
Free Cash Flow (TTM)
$237.4M
Gross Margin
—
Operating Margin
42.8%
Net Margin
53.9%
ROE
17.6%
ROIC
39.4%
Debt / Equity
—
Net Cash
$823.4M
Return 1Y
+136.3%
Company profile
Krystal Biotech, Inc. engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105, KB301, KB407, KB104, KB5xx and KB3xx product.
- CEO
- Krish S. Krishnan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 210
- Headquarters
- Pennsylvania
- Website
- krystalbio.com
Management & directors
- Thomas John CharlesEVP, General Counsel
- Krishnan Krish SPresident and CEO
- Krishnan SumaPresident, R&D
- Romano KathrynChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
KRYS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$116.4M↑ +31.9%
Diluted EPS$1.83↑ +52.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $50.7M | $290.5M | $389.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$33.0M | -$68.3M | -$145.2M | -$109.6M | $65.7M | $161.3M |
| Net income | -$32.2M | -$69.6M | -$140.0M | $10.9M | $89.2M | $204.8M |
| Diluted EPS | -$1.71 | -$3.13 | -$5.49 | $0.39 | $3.00 | $6.84 |
| Operating cash flow | -$26.1M | -$47.9M | -$100.6M | -$88.8M | $123.4M | $200.9M |
| Free cash flow | -$40.9M | -$116.3M | -$153.5M | -$100.6M | $119.2M | $188.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -216.2% | 22.6% | 41.5% |
| Net margin | — | — | — | 21.6% | 30.7% | 52.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.3M | $83.8M | $91.1M | $88.2M | $96.0M | $97.8M | $107.1M | $116.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $8.6M | $22.5M | $41.4M | $36.3M | $39.3M | $41.4M | $44.4M | $53.7M |
| Net income | $15.6M | $27.2M | $45.5M | $35.7M | $38.3M | $79.4M | $51.4M | $55.9M |
| Diluted EPS | $0.53 | $0.91 | $1.53 | $1.20 | $1.29 | $2.66 | $1.69 | $1.83 |
| Operating cash flow | -$4.2M | $58.9M | $52.8M | $31.0M | $52.7M | $39.7M | $77.5M | $80.4M |
| Free cash flow | -$5.3M | $57.8M | $52.0M | $24.8M | $50.8M | $38.0M | $75.4M | $73.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 12.2% | 26.8% | 45.4% | 41.1% | 40.9% | 42.3% | 41.4% | 46.1% |
| Net margin | 22.2% | 32.4% | 49.9% | 40.5% | 39.9% | 81.2% | 48.0% | 48.1% |
Company news
Jul 1, 2026
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-25 | Thomas John Charles· EVP, General Counsel | Sale | 1,000 | $347.27 | $347,270.00 | filing |
| 2026-06-25 | Thomas John Charles· EVP, General Counsel | Option exercise | 1,000 | $179.25 | $179,250.00 | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 12,729 | $307.81 | $3.9M | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 11,461 | $307.68 | $3.5M | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 4,830 | $308.47 | $1.5M | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 3,803 | $308.89 | $1.2M | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 2,801 | $309.95 | $868,156.23 | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 2,784 | $309.49 | $861,620.44 | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 2,652 | $310.43 | $823,257.71 | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 2,039 | $310.94 | $634,000.54 | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 1,348 | $307.09 | $413,963.79 | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 964 | $311.36 | $300,149.11 | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 640 | $302.24 | $193,431.49 | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 589 | $306.33 | $180,429.43 | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 593 | $302.25 | $179,234.72 | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 544 | $304.81 | $165,816.75 | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 480 | $305.87 | $146,815.20 | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 400 | $304.89 | $121,957.56 | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 320 | $300.75 | $96,240.00 | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 320 | $300.75 | $96,240.00 | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 247 | $303.17 | $74,883.06 | filing |
| 2026-06-04 | Krishnan Suma· President, R&D | Sale | 240 | $311.65 | $74,796.00 | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 176 | $303.17 | $53,357.73 | filing |
| 2026-06-04 | Krishnan Krish S· President and CEO | Sale | 40 | $312.23 | $12,489.20 | filing |
| 2026-05-26 | Thomas John Charles· EVP, General Counsel | Sale | 642 | $302.03 | $193,903.26 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.